Conventional medicines treat the symptoms instead of the cause of diseases, meaning that patients must be treated throughout their lives. We are working to develop one-time treatments that target the cause of diseases.
Genome Editing Resources
The resources below provide background information regarding cell and gene therapies, the CRISPR/Cas9 technology and Intellia’s genome editing work.
Intellia is developing therapies that edit patients’ somatic cells, which are the non-reproductive cells, to permanently treat their disease without impacting their progeny. Our therapies will not seek to edit patients’ germline or reproductive cells. (Changes to germline cells could be passed down to future generations.) Read Intellia’s full statement here.
Resources for the Transthyretin Amyloidosis Community
We are proud to work closely with the following organizations so that we can better understand the needs of patients and their families and caregivers. These organizations can also provide you additional information and access to transthyretin amyloidosis (ATTR) research and support.
Resources for the Acute Myeloid Leukemia Community
Click the links below for more information about acute myeloid leukemia, Intellia’s second development program.
“Guide to Leukemia – Acute Myeloid – AML”
American Society of Clinical Oncology
“Adult Acute Myeloid Leukemia Treatment (PDQ®)–Patient Version”
National Cancer Institute
“Acute Myeloid Leukemia Disease Information”
Leukemia & Lymphoma Society
“What is AML?”
Resources for the Hereditary Angioedema Community
Click the links below for more information about hereditary angioedema, Intellia’s third development program.
“Your Guide to Understanding Genetic Conditions: Hereditary Angioedema”
NIH, U.S. National Library of Medicine – Genetics Home Reference
NIH, National Cancer for Advancing Translational Sciences – Genetic and Rare Disease Information Center
“What is HAE?”
US Hereditary Angioedema Association
“What is HAE?”